
BNTC Stock Forecast & Price Target
BNTC Analyst Ratings
Bulls say
Benitec Biopharma Inc. is positioned favorably due to its promising advancements in developing BB-301, a therapeutic targeting Oculopharyngeal Muscular Dystrophy, reflected in highly positive interim clinical data. The increasing probability of regulatory approval has risen to 45%, indicative of a strong likelihood for accelerated market access based on observed clinical efficacy and the potential for premium pricing due to the treatment's value proposition. Additionally, the sustained improvements in patient outcomes, including enhanced swallowing capabilities, underscore the long-term therapeutic benefits of BB-301, supporting a favorable outlook for continued investment and growth.
Bears say
Benitec Biopharma Inc has reported a first quarter net loss of $0.21 per share, which, despite being better than the forecast of $0.41, highlights ongoing financial strain attributed to a higher-than-expected share count. The company faces significant risks related to its developmental therapy BB-301, including potential delays in clinical trials, negative study data, and challenges in obtaining regulatory approval, all of which could negatively affect market perception and share value. Additionally, there are concerns regarding medium- to long-term dilution risks and slower-than-anticipated market uptake for their therapeutic, contributing to the analyst's cautious outlook on the company's financial future.
This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
BNTC Analyst Forecast & Price Prediction
Start investing in BNTC
Order type
Buy in
Order amount
Est. shares
0 shares